Navigation Links
Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
Date:9/22/2011

SAN DIEGO, Sept. 22, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that management will be presenting at the JMP Securities Healthcare Conference in New York. The presentation is scheduled for Wednesday, September 28 at 8:30 a.m. EDT (5:30 a.m. PDT). To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the company's Web site at www.halozyme.com. A replay will be available for 90 days after the event.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze(TM) technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche, Baxter, ViroPharma and Intrexon to apply Enhanze technology to therapeutic biologics including Herceptin®, MabThera®, immunoglobulin, Cinryze® and recombinant human alpha 1-antitrypsin. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant un
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
2. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
4. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
5. Halozyme Therapeutics to Host Research Day for Investors and Analysts
6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
8. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
9. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
10. Halozyme Receives $5.5 Million Payment From Baxter
11. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... PRC Clinical, a full-service, ... Bay Area, will exhibit and present at the ... on March 25th and 26th in Tel Aviv, Israel. ... Israeli life science companies seeking to conduct U.S. Food ... span all phases of human trials, from Phase I ...
(Date:3/4/2015)... March 4, 2015  BioClinica®, Inc., a ... provider, today announced that clinical trial professionals ... at its annual European User Conference in ... discuss the use of its eClinical technologies ... technologies include: the Microsoft Office-Smart OnPoint CTMS; ...
(Date:3/4/2015)... PARIS , March 4, 2015 ... de Paris in December 2011, ... study of yttrium-90 resin microspheres versus sorafenib in advanced ... results expected late 2016.   SARAH, a ... liver cancer (hepatocellular carcinoma, or HCC) has completed patient ...
(Date:3/3/2015)... 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: ... diagnostics that target the underlying mechanisms of cancer, today ... ended December 31, 2014. Effective July 17, ... May 31 to December 31. As a result of ... for the quarter and the seven months ended December ...
Breaking Biology Technology:PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
... all over the world will gather at Florida ... focuses on predicting the properties of materials and ... More than 500 materials science scholars and professionals ... problems and development of innovative theoretical and computational ...
... ultimate miniaturisation of computer memory: storing information inside the ... step in bringing to life a quantum computer - ... mechanics which could crack problems unsolvable by current technology. ... are allowed to exist in multiple states simultane-ously -- ...
... -, Third Quarter 2008 Highlights:, -- Total revenues of ... Total revenues without Osteocel of $62.5 million; up 62.3% from the ... of $54.7 million; up 73.2% from the third quarter of 2007, ... of 2007, -- GAAP loss per share for the quarter ...
Cached Biology Technology:FSU scientific computing department hosts international conference 2FSU scientific computing department hosts international conference 3Memoirs of a qubit: Hybrid memory solves key problem for quantum computing 2Nuvasive Reports Third Quarter 2008 Financial Results 2Nuvasive Reports Third Quarter 2008 Financial Results 3Nuvasive Reports Third Quarter 2008 Financial Results 4Nuvasive Reports Third Quarter 2008 Financial Results 5Nuvasive Reports Third Quarter 2008 Financial Results 6Nuvasive Reports Third Quarter 2008 Financial Results 7Nuvasive Reports Third Quarter 2008 Financial Results 8Nuvasive Reports Third Quarter 2008 Financial Results 9Nuvasive Reports Third Quarter 2008 Financial Results 10Nuvasive Reports Third Quarter 2008 Financial Results 11Nuvasive Reports Third Quarter 2008 Financial Results 12
(Date:2/23/2015)... OXFORD, Conn. , Feb. 23, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... it has filed provisional patent 62114357 for ... With this patent, NXT-ID introduces a new groundbreaking payment ... and the payment account may only be accessed if ...
(Date:2/12/2015)... Conn. , Feb. 12, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... has filed provisional patent 62/113114 for DISTRIBUTED ... DEVICES. The patent further establishes NXT-ID,s position ... its intellectual property portfolio the ability for multiple devices ...
(Date:2/5/2015)... 2015  Marken is starting its 35 th ... a new marketing campaign to solidify its place as ... campaign focuses on First as a primary ... The first headline in the series, ... its client,s priorities. Marken recognizes the need to protect ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2
... effort to achieve breakthrough innovations in energy production, U.S. Deputy ... up to $122 million over five years to a multidisciplinary ... aimed at developing revolutionary methods to generate fuels directly from ... (JCAP), to be led by the California Institute of Technology ...
... clear of crocodiles and navigating around massive submerged trees, ... 25 freshwater pools of Cara Blanca, Belize, which were ... May, the divers found fossilized animal remains, bits of ... an enormous underwater cave. [Click here to ...
... This release is available in German ... have successfully measured in the ozone layer the chlorine ... ozone depletion. The doubts in the established models of ... laboratory measurements are disproved by these new atmospheric observations. ...
Cached Biology News:California team to receive up to $122 million to develop method to produce fuels from sunlight 2California team to receive up to $122 million to develop method to produce fuels from sunlight 3Extreme archaeology: Divers plumb the mysteries of sacred Maya pools 2Extreme archaeology: Divers plumb the mysteries of sacred Maya pools 3Key compound of ozone destruction detected 2
ma. plate stack height 70mm...
... MBS Satellite Thermal Cycler (MBS) ... solution for medium to high ... combines the latest in satellite ... and PC control, resulting in ...
45° Fixed Angle Rotor for use in the IEC Centra CL2, Centra CL3/CL3R, HN-SII, and the Centra-MP4/MP4R....
Glycerokinase; from Bacillus stearothermophilus...
Biology Products: